Philips Starts 2026 with Solid Q1 Growth, Margin Expansion and Renewed Outlook

Koninklijke Philips ( (PHG) ) has issued an announcement.

Philips reported first-quarter 2026 results on May 6, 2026, delivering a 6% increase in comparable order intake and 4% comparable sales growth to EUR 3.9 billion, with income from operations rising to EUR 241 million and an adjusted EBITA margin of 9.0%. Growth was broad-based across segments and regions, led by Personal Health and strong demand in North America and Europe, while free cash flow reached EUR 28 million.

Segment performance was mixed, with Diagnosis & Treatment sales up 2% and margin improving to 9.8%, Connected Care sales up 3% but margin slipping to 2.9%, and Personal Health sales climbing 9% with margin rising to 15.8% despite tariff and inflation headwinds. Management stressed disciplined execution and productivity, delivering EUR 126 million in quarterly savings and keeping the company on track for its 2026–2028 EUR 1.5 billion cost program.

The quarter underscored Philips’ innovation and MedTech positioning, as it retained the No. 1 MedTech patent rank in Europe and secured multiple FDA 510(k) clearances for AI-driven cardiology and CT imaging solutions including DeviceGuide, SmartHeart, Verida Spectral CT and Rembra CT. In consumer health, Philips expanded its Sonicare portfolio with new accessible and premium toothbrush ranges in the U.S. and China, reinforcing leadership in oral care and leveraging platform-based product strategies.

Philips also deepened its strategic ties with major U.S. health systems, signing long-term partnerships with WellSpan Health, University Health San Antonio and AdventHealth covering imaging platforms and enterprise monitoring services across extensive care networks. These agreements support standardization, lifecycle management and data-driven workflows, strengthening Philips’ role as a preferred technology partner and enhancing recurring service and platform revenues.

Looking ahead, Philips reiterated its full-year 2026 outlook for 3%–4.5% comparable sales growth, a 12.5%–13.0% adjusted EBITA margin and EUR 1.3–1.5 billion in free cash flow, while acknowledging macro uncertainty and tariff pressures but excluding potential tariff refunds and Philips Respironics-related proceedings. To meet obligations under long-term incentive plans, the company plans to repurchase up to 4 million shares, valued at about EUR 91 million at current prices, via forward transactions in the second and/or third quarter of 2026, signaling continued capital discipline and confidence in its strategic plan.

The most recent analyst rating on (PHG) stock is a Buy with a $30.30 price target. To see the full list of analyst forecasts on Koninklijke Philips stock, see the PHG Stock Forecast page.

Spark’s Take on PHG Stock

According to Spark, TipRanks’ AI Analyst, PHG is a Neutral.

PHG scores as moderately attractive, led by a clear 2025 profitability recovery and a supportive technical uptrend. The score is capped by multi-year earnings and cash-flow volatility and meaningful 2026 headwinds (tariffs and Respironics-related uncertainty), while the ~3% dividend provides some valuation support despite a negative P/E.

To see Spark’s full report on PHG stock, click here.

More about Koninklijke Philips

Koninklijke Philips, branded as Royal Philips, is a Netherlands-based health technology and consumer products company focused on medical imaging, image-guided therapy, patient monitoring, and personal health devices such as oral care and grooming. The group targets hospitals, health systems and consumers globally, with a strong MedTech innovation pipeline that combines hardware, software and AI across Diagnosis & Treatment, Connected Care and Personal Health segments.

Average Trading Volume: 1,105,923

Technical Sentiment Signal: Sell

Current Market Cap: $25.02B

Learn more about PHG stock on TipRanks’ Stock Analysis page.